Supplementary Material for: Telitacicept in IgA Nephropathy Patients with Severe Renal Imp

A figshare admin karger uploaded a case series document on 2026-04-21. The material supports a study of 13 patients with severe IgA nephropathy treated with telitacicept between March 2023 and June 2024. It includes longitudinal data on proteinuria, estimated glomerular filtration rate, and serum immunoglobulins.

Use Cases

• Analyzing proteinuria reduction trends based on longitudinal measurements mentioned in the description
• Evaluating renal function stability based on eGFR decline slopes reported over 24 months
• Comparing treatment efficacy based on combination therapy versus monotherapy outcomes described
• Studying immunological response based on changes in serum IgA and IgG levels documented

Strengths

• Includes longitudinal data for 13 patients over up to 24 months
• Reports specific quantitative outcomes: proteinuria decreased by 45-51% and eGFR annual decline slope of -2.39 mL/min/1.73 m²/year
• Provides immunological data: serum IgA fell from 2.93 ± 0.78 to 0.78 ± 0.28 g/L in a subset of patients

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data scale is limited to a 160.6 KB document file, suggesting a small case series

Provenance

Source

figshare admin karger

Collection Method

Retrospective medical record review

Time Range

March 2023 to June 2024 (treatment period), with follow-up through at least 24 months

Freshness

Last updated 2026-04-21 05:55:12; freshness should be verified